Ovid Therapeutics Inc
Biotechnology
Ovid Therapeutics Inc (OVID) Stock News
The latest OVID headlines and market coverage — 10 recent stories, updated throughout the day.
- The Motley Fool·
Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice
Moderna is transitioning from a COVID-19 vaccine company to an oncology-focused biotech firm. The company announced positive phase 3 results for its personalized cancer vaccine (intismeran autogene) paired with Merck's Keytruda for melanoma treatment. With the global oncology market projected to grow from $253 billion to over $700 billion by 2034, Moderna's stock has surged over 600% this year, though it now trades 61% above Wall Street's average price target of $123.
- Zacks Investment Research·
Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?
Moderna reported positive Phase III results for its personalized mRNA cancer therapy (intismeran autogene) developed with Merck, showing significant improvements in recurrence-free and distant metastasis-free survival in melanoma patients. The breakthrough validates Moderna's mRNA platform beyond vaccines and opens opportunities across multiple tumor types, while the company simultaneously expands its respiratory vaccine portfolio with RSV, flu, and combination vaccines to reduce COVID-19 dependence.
- GlobeNewswire Inc.·
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041
AIM ImmunoTech announced patent protection for Ampligen across 18 European countries and the United Kingdom through June 2041 for Long COVID treatment. The company also recently secured a U.S. patent for Ampligen combined with pembrolizumab for cancer treatment. These patents strengthen AIM's global intellectual property position around its dsRNA immunomodulator platform across multiple therapeutic indications.
- The Motley Fool·
$5,000 in Bloom Energy at Its COVID-Era Low Would Be Worth This Much Now
Bloom Energy reported its strongest quarter ever with revenue crossing $1 billion for the first time. The stock has surged significantly this year, with a $5,000 investment from the COVID-era low of $3 per share in March 2020 now worth approximately $337,000—a 63-fold gain. While the stock has rallied substantially, analysts caution that such returns are unlikely to repeat and recommend keeping expectations realistic.
- GlobeNewswire Inc.·
ARCPOINT PROVIDES LEADERSHIP UPDATE
Peter Kendall has completed his mandate as Interim Chief Executive Officer of ARCpoint Inc. after 45 days, delivering his assessment and recommendations to the Board. His RSU grant has been pro-rated from 4 million to 2 million shares. The Board is now considering his recommendations and will seek to appoint a new CEO. Kendall will continue as an advisory consultant.
- Benzinga·
GO RESIDENTIAL REIT COMPLETES STRATEGIC TRANSACTIONS TO INCREASE SCALE, PROVIDE IMMEDIATE ACCRETION, AND GROW ITS UNENCUMBERED POOL OF ASSETS AND ANNOUNCES JUNE 2026 CASH DISTRIBUTION
GO Residential REIT completed acquisitions of 7 Dey Street in Tribeca and Ivy Tower in Times Square, increasing its portfolio to 2,545 residential suites (26% growth). The transactions are expected to be immediately accretive to AFFO per unit and were funded through available cash and $146.3 million in fixed-rate mortgage debt at 4.50%. The REIT approved a monthly cash distribution of $0.05325 per unit for June 2026.
- Benzinga·
NORTHSTAR REPORTS FIRST QUARTER 2026 RESULTS; PROVIDES CAPITAL MARKETS UPDATE AND ANNOUNCES WEBCAST
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR THE DISSEMINATION, DISTRIBUTION, RELEASE OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES/ CALGARY, AB , June 1, 2026 /CNW/ - Northstar Clean Technologies Inc. (TSXV: ROOF ) (OTCQB: ROOOF ) (" Northstar " or the " Company ") is pleased to announce its financial and operating results for the three-month period ended March 31, 2026. Selected financial and operational information is set out below and should be read in conjunction with the Company's March 31, 2026 financial statements and the related management's discussion and analysis, which are available for review at www.sedarplus.ca or the Company's website at www.northstarcleantech.com . "The first quarter of 2026 was focused on strategic execution for Northstar, highlighted by the advancement of our U.S. expansion plans, including the selection of Baltimore, MD as our first U.S. location, and the strengthening of our financial position to support the ramp up of the Empower Calgary facility and future growth," said Aidan Mills, President & CEO of Northstar. "This month, ramp up activities at the Empower Calgary Facility have been ongoing and, we're successfully processing front-to-back without encountering the material transfer and water processing issues initially at 80tpd. We're getting very close to achieving 100tpd at the Calgary Facility, a key operational milestone aligned with ERA Milestone 4 and an important step toward commercial production." Q1 2026 Highlights January 2026: Northstar Selects Baltimore, Maryland as First United States Expansion Location January 2026: Northstar Raises $1.0 Million in Debenture Proceeds February 2026: Northstar Extends Maturing Convertible Debentures March 2026: Northstar Announces US$10 Million Non-Binding Term Sheet March 2026: Northstar Closes US$9 Million First Tranche of US$10 Million
- Benzinga·
SOURCE ROCK ROYALTIES ANNOUNCES FIRST QUARTER 2026 RESULTS AND PROVIDES CORPORATE UPDATE
/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE U.S./ CALGARY, AB , June 1, 2026 /CNW/ - Source Rock Royalties Ltd. ("Source Rock") (TSXV: SRR ), a pure-play oil and gas royalty company with an established portfolio of oil royalties and Crown mineral leases, announces results for the three-month period ended March 31, 2026 ("Q1 2026"). President's Message - Corporate Update During Q1 2026, we experienced two very different market environments. Oil prices were below $60.00 USD per barrel in January and remained very weak for almost all of February; which followed extended oil price weakness throughout the second half of 2025. These prolonged lower oil prices resulted in less new drilling activity on our royalty lands and reduced new production to offset natural declines from consistent drilling activity in 2024 and the first half of 2025. In addition, our production volume royalty had a scheduled decline from 70 bbl/d to 39 bbl/d that went into effect on January 1, 2026. This weakness reversed quickly when oil prices spiked in March, which changed the dynamic across our royalty lands for the first quarter and improved our outlook for the remainder of 2026. March royalty production rebounded from earlier in Q1 2026 to average 204 boe/d and royalty revenue for the month was approximately $623,000. Seven new horizontal wells began producing in March on our central Alberta (4) and S.E. Saskatchewan (3) royalty lands. The higher oil price environment not only increases the royalty revenue from our existing production due to our ~90% oil royalty production ratio, but it also positively changes our expectations for new drilling on our royalty lands. In particular, the operator of our Clearwater royalty lands recently disclosed that they have added a second rig to the property and anticipate an increase in the number of Clearwater horizontal wells to b
- Benzinga·
COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
REHOVOT, Israel , May 29, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN ), a regenerative and medical aesthetics company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and medical aesthetics applications, today announced financial results for the first quarter of 2026 and provided a corporate update. "In the first quarter of 2026, we initiated discussions with several leading strategic players to explore potential collaborations, primarily in the medical aesthetics field," said Yehiel Tal, Chairperson and Chief Executive Officer of CollPlant Biotechnologies. "These discussions are focused on the potential joint development and commercialization of next-generation dermal filler product candidates incorporating CollPlant's rhCollagen technology in combination with hyaluronic acid and additional components. We are actively advancing these discussions and, while no assurance can be provided, remain encouraged by the level of interest and the progress achieved to date." Mr. Tal continued: "CollPlant is also advancing development of its next-generation photocurable dermal filler platform based on rhCollagen technology, designed to provide immediate structural support together with the potential for long-term tissue regeneration. The product candidate, currently in the final preclinical stage, is intended to address age-related volume loss and facial changes associated with significant weight reduction. During the quarter, the Korean Patent Office granted CollPlant a patent covering key aspects of the photocurable dermal filler technology, further strengthening our intellectual property portfolio in regenerative aesthetics." "The Company is planning to establish a broader portfolio of regenerative dermal and soft tissue fillers and is targeting initiation of clinic
- Benzinga·
Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes
Virax Biolabs Group Limited announced positive early pilot data for ViraxImmune™, a blood-based diagnostic test for Long COVID and related post-acute infection syndromes. The test demonstrated 88% specificity and 92% positive predictive value in separating PAIS patients from healthy controls across 120+ subjects. The company plans a larger clinical validation study with 300 additional participants, with analysis expected in Q4 2026 and results in Q1 2027, targeting a U.S. Laboratory Developed Test market entry.